Basilea Pharmaceutica Ltd, Allschwil, Switzerland
www.basilea.com

NOVEL CLASS ANTIBIOTIC TARGETING LPTA

Treatment of Enterobacteriaceae infections
Basilea is developing a novel antibiotic for the treatment of severe bacterial infections caused by Gram-negative bacteria. The therapeutic is derived from a natural product and belongs to a novel class. It works on a novel target called lipopolysaccharide transport protein A (LptA) and selectively disrupts the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. This antibiotic shows potent activity against Enterobacteriaceae, including extremely drug-resistant strains. Enterobacteriaceae are a large family of important pathogens such as Escherichia coli and Klebsiella pneumoniae causing life-threatening infections including bloodstream infections and pneumonia. The CARB-X award will support the development of the antibiotic towards preclinical candidate nomination.

Current Development Stage: Pre-Clinical

CARB-X Investment: Initial investment of up to $2.62m, with potential option payments up to $15.82m.

Initial CARB-X Investment Date: August 1,  2020